Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 6Phase 3 3Phase 1/2 2Phase NA 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

NETWORK 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Lung Neoplasms 10Prostatic Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Biphenotypic, Acute 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Melanoma 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Carcinoma, Renal Cell 3Burkitt Lymphoma 3Brain Neoplasms 3Ureteral Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Rhabdomyosarcoma 2Oropharyngeal Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Mouth Neoplasms 2Medulloblastoma 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Hematopoietic and Lymphatic System Neoplasm 2Glioblastoma 2Ganglioneuroblastoma 2Fallopian Tube Neoplasms 2

Interventions

Cyclophosphamide 24Vincristine 19Doxorubicin 17Radiotherapy 14Prednisone 13Methotrexate 13Cytarabine 13Rituximab 11Dexamethasone 11pegaspargase 10Filgrastim 10Etoposide 10Mercaptopurine 9Calcium Dobesilate 9merphos 8dexamethasone acetate 8dexamethasone 21-phosphate 8azathiopurine 8auricularum 8Thioguanine 8Leucovorin 8Radiation 7Daunorubicin 7prednylidene 6deltacortene 6Asparaginase 6blinatumomab 5Prednisolone 5Peripheral Blood Stem Cell Transplantation 5calaspargase pegol 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Burkitt Lymphoma × Specimen Handling × Clear all
NCT05602194 2026-06-02

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

Children's Oncology Group

Phase 3 Active not recruiting
440 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02003222 2026-05-28

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
488 enrolled 13 charts 1 FDA
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡